Etravirine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Etravirine: From HIV-1 Infection to Simian Immunodeficiency Virus (SIV) Infection
One-Sentence Summary
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for treatment-experienced HIV-1 infection. The TxGNN model’s top-ranked prediction is Simian Immunodeficiency Virus (SIV) Infection — a primate-only pathogen with no human clinical role — supported by 0 clinical trials and 1 preclinical publication, so despite a near-maximal model score this specific top-ranked signal should be read as a knowledge-graph artefact rather than an actionable human indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 infection (NNRTI antiretroviral therapy in treatment-experienced adults, per trial records in the evidence pack) |
| Predicted New Indication | Simian immunodeficiency virus infection |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Etravirine is not available in this evidence pack. Based on the information present, Etravirine is an NNRTI-class antiretroviral whose efficacy against treatment-experienced HIV-1 infection is well established; mechanistically, NNRTIs act by binding the viral reverse transcriptase enzyme, so in principle any lentivirus with a structurally similar reverse transcriptase could be susceptible.
SIV is the model’s rationale here: it is a primate lentivirus that is structurally homologous to HIV-1’s reverse transcriptase, so an NNRTI could theoretically show cross-activity. However, SIV is an animal model virus used in laboratory and primate research — it does not infect humans, so there is no realistic clinical pathway from this prediction to a human therapeutic indication. The single supporting reference is an in vitro/preclinical nanoparticle drug-delivery study that is not even specific to SIV. This combination (extremely high score, essentially no supporting evidence, non-human disease target) is a hallmark of embedding-space noise rather than a genuine repurposing opportunity.
It is worth noting that this same evidence pack contains a materially stronger, human-relevant signal further down the ranked list: AIDS related complex (rank 4, evidence level L2, 1 completed Phase-related trial plus 2 literature references, recommendation “Proceed with Guardrails”). That candidate sits squarely within Etravirine’s known HIV-1 disease spectrum and may warrant separate evaluation, but it falls outside the scope of the rank-1 candidate discussed in this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26529558 | 2015 | In vitro/Preclinical | Molecular pharmaceutics | Nanoparticle-based antiretroviral drug combinations for synergistic inhibition of cell-free and cell-cell HIV transmission; not SIV-specific and not a clinical study. |
UK Market Information
No marketing authorisations are recorded in the evidence pack for this product. UK market status: Not Marketed (0 licences on file).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Although the TxGNN score for this candidate is very high (99.98%), the predicted indication — SIV infection — is a non-human disease with no clinical development pathway, and it is supported only by a single, non-specific preclinical publication with no clinical trial evidence. This does not meet the threshold to advance.
To proceed, the following is needed:
- DrugBank-sourced mechanism of action data for Etravirine (currently missing, flagged as High severity in the evidence pack)
- MHRA/SmPC warnings, contraindications and drug interaction data (currently missing, flagged as Blocking — required before any safety pre-screen)
- If repurposing evaluation continues for this drug, redirect focus to the higher-evidence, human-relevant candidate identified in the same batch (AIDS related complex, evidence level L2), rather than the SIV signal reviewed here
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.